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OPIOID PEPTIDES
Janice C. Froehlich, Ph.D.
Opioid peptides produced in the body act as neuro-
modulators that modify the actions of other neuro-
transmitters in the central nervous system. By altering
the electrical properties of their target neurons, there-
by making these neurons more difficult to excite, opi-
oid peptides can influence the release of various
neurotransmitters. As a result of this modulation, opi-
oid peptides can—among other functions—induce
pain relief and euphoria as well as affect certain be-
haviors, including alcohol consumption. Alcohol can
activate the opioid peptide system. This mechanism
may contribute to alcohol reinforcement and exces-
sive alcohol consumption, because agents that inhibit
the opioid peptide system decrease alcohol self-
administration in animals and reduce craving and al-
cohol consumption in human alcoholics. Moreover, a
genetically determined, increased responsiveness of
the opioid system to alcohol may contribute to a pre-
disposition for alcoholism in some people. KEY WORDS:
endogenous opioids; peptides; drug interaction; neuro-
transmitters; opioid receptors; central nervous system;
brain; neuron; biological activation; reinforcement;
AOD use behavior; self administration of drugs; AOD
craving; AOD sensitivity; AOD use susceptibility; eu-
phoria; sense of pain; literature review
Endogenous opioid peptides1 are small molecules thatare naturally produced in the central nervous system(CNS) and in various glands throughout the body,
such as the pituitary and adrenal glands. These peptides
produce the same effects as the chemicals known as classic
alkaloid opiates, which include morphine and heroin.
Endogenous opioid peptides function both as hormones
and as neuromodulators. Endogenous opioid peptides that
serve as hormones are secreted into the circulation by the
producing glands and are delivered to a variety of distant
target tissues where they induce a response. Endogenous
opioid peptides that serve as neuromodulators are produced
and secreted by nerve cells (i.e., neurons) and act in the
brain and spinal cord to modulate the actions of other
neurotransmitters. (For more information on these neuro-
transmitters, see the related articles in this section.)
Through these two mechanisms, endogenous opioid pep-
tides produce many effects, ranging from preventing diar-
rhea to inducing euphoria and pain relief (i.e., analgesia).
This article reviews the physiology of endogenous opi-
oid peptides and their interactions with other neurotrans-
mitters. In addition, the article summarizes the interactions
between alcohol and the endogenous opioid system and
presents evidence that opioid peptides play a role in alco-
hol reinforcement. (For further information on alcohol and
the opioid system, see Froehlich and Li 1993, 1994;
Gianoulakis and colleagues 1996a; Herz 1997.)
PHYSIOLOGY OF OPIOID PEPTIDES
Opioid Peptide Production
Many peptides with opioidlike effects have been found in
the CNS and in peripheral tissues. Molecular biological
approaches, such as recombinant DNA techniques, have
demonstrated that these peptides fall into three categories—
enkephalins, endorphins, and dynorphins—that are derived
from three distinct precursor molecules. The active, func-
tional opioid peptides are generated from their precursors
by enzymes called peptidases, which cut these precursor
molecules into smaller entities. The peptides are then modi-
fied further during posttranslational processing, which can
include the addition of various chemical groups to the pep-
tides (e.g., sugar molecules [i.e., glycosylation], acetyl
groups [i.e., acetylation], phosphate groups [i.e., phosphory-
lation], or methyl groups [i.e., methylation]). These modifi-
cations can alter the peptides’ biological activities. Because
the processing of opioid peptides from larger precursor
molecules is very selective, the opioid-peptide profiles can
vary among different tissue types.
So far, two of the enkephalins (i.e., leu-enkephalin and
met-enkephalin) and one of the endorphins (i.e., beta-
endorphin) have been shown to be active in mediating
alcohol’s effects.
Opioid Receptors
To affect the functions of their target cells, opioid peptides
must bind to specific molecules, or receptors, on the sur-
faces of these cells. The body contains several receptors
that selectively recognize molecules with opioidlike struc-
tures. Three major categories of opioid receptors—mu,
delta, and kappa—have been identified that differ both in
their functions and in their binding characteristics. A given
opioid peptide can interact with more than one type of
opioid receptor. The binding of opioid peptides to these
receptors initiates a series of biochemical events that cul-
minate in various effects, including analgesia and euphoria.
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Site of Action of Opioid Peptides
Anatomical Distribution in the Brain. Not all opioid pep-
tide-containing neurons are located in the same brain areas.
For example, neurons that contain enkephalins have been
found in many different brain regions, suggesting that these
peptides are involved in many physiological functions (see
figure 1). For example, enkephalins mediate pain percep-
tion by acting in the spinal cord and in the periaqueductal
gray (PAG) region of the brain. In addition, enkephalins
alter emotional responses by acting in limbic areas, such as
the amygdala, and alter cardiovascular or respiratory func-
tions by acting on autonomic nuclei in the hypothalamus
and brain stem. Most enkephalin-containing neurons have
short axons, indicating that enkephalins act close to their
points of synthesis.
The distribution of neurons containing the other two
types of opioid peptides—beta-endorphin and the dynor-
phins—is not as diffuse as that of the neurons containing
enkephalins. Neurons that contain beta-endorphin are
found predominately in the hypothalamus and in a region
of the brain stem (i.e., the nucleus of the solitary tract) (see
figure 2). The dynorphin-containing neurons are located
primarily in the hypothalamus. In contrast to the
enkephalin-containing neurons, those that contain beta-
endorphin or dynorphins have long axons that extend to
distant brain regions as well as to the pituitary gland, brain
stem, and spinal cord, indicating that beta-endorphin and
dynorphins act distant from their points of synthesis.
Anatomical Distribution in the Periphery. All three types
of opioid peptides (i.e., enkephalins, endorphins, and
dynorphins) are found in the pituitary and adrenal glands.
Although many stimuli can induce the pituitary to release
opioid peptides into the circulation, the precise function of
these peptides in their peripheral target tissues is not well
understood. Opioid peptides have been found in many
organ tissues throughout the body, including the heart,
pancreas, placenta, kidneys, and gastrointestinal organs.
Mechanism of Action of Opioid Peptides
Once released from the neurons, opioid peptides act
through opioid receptors on their target neurons to transmit
messages that primarily inhibit secondary systems, such as
pain perception (see below). In addition, opioid peptides
can induce the following effects:
• Decrease respiration
• Stimulate or depress cardiovascular functioning, de-
pending on the brain area where the opioid peptides act
• Decrease the movement (i.e., motility) of the muscles of
the gastrointestinal (GI) tract, thereby slowing down the
food’s transit through the GI tract
• Decrease susceptibility to seizures
• Induce euphoria
• Affect certain behaviors, such as the consumption of
food and alcohol.
Pain Control Systems. Endogenous opioid peptides induce
analgesia in humans and antinociception in animals.2 These
peptides act in several regions of the CNS to mediate pain
control, because antinociception is observed in animals
whether endogenous opioid peptides are administered into
the peripheral circulation; into spinal sites; or into various
regions of the brain, such as the raphe nuclei, PAG region,
or medial preoptic area. 
Many events or stimuli that are experienced as painful,
stressful, or traumatic can induce the release of endoge-
nous opioid peptides. These peptides then act to make
humans and animals less sensitive to noxious events by
inducing euphoria and analgesia or antinociception.
Evidence suggests that acupuncture induces analgesia by
stimulating the release of endogenous opioid peptides. For
example, chemicals that inhibit opioid receptor function
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Figure 1 Schematic representation of a rat brain illustrating
the distribution of enkephalin-containing neurons.
These neurons originate in numerous brain
regions (indicated by black circles) and terminate
either in the same regions or in distant regions
(indicated by shaded areas).
NOTE: CA=commissura anterior; coe=ceruleus n.; cp=n. caudatus
putamen; fm=n. paraventricularis pars magnocellularis; gp=globus
pallidus; hl=n. lateralis hypothalami; ml=n. mammilaris lateralis;
oli=n. olivaris; po=n. pontis; rd=n. reticularis dorsalis medullae
oblongatae; rtp=n. reticularis tegmenti pontis; rv=n. reticularis
ventralis medullae oblongatae; SNC=substantia nigra zona
compacta; sol=n. tractus solitarii; sut=n. subthalamicus; tav=n.
anterior ventralis thalami; td=n. tractus diagonalis; tl=n. lateralis
thalami; tlp=n. lateralis thalami, pars posterior; VII=n. nervi facialis;
VIIIm=n. vestibularis medialis; VIIIs: n. vestibularis superior.
SOURCE:  Adapted from Sar, M.; Stumpf, W.E.; Miller, R.J.;
Chang, K.-J.; and Cuatrecasas, P. Immunohistochemical
localization of enkephalin in rat brain and spinal cord. Journal of
Comparative Neurology 182:17–38, 1978.
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(i.e., opioid receptor antagonists) have been shown to re-
verse the analgesia induced by acupuncture. Similarly, the
action of inactive substances, or placebos, in reducing pain
may result from the placebo-induced release of endogenous
opioid peptides in anticipation of pain relief. This hypothe-
sis is supported by the fact that opioid receptor antagonists
reverse the pain relief experienced with placebos. 
INTERACTIONS BETWEEN OPIOID PEPTIDES
AND OTHER NEUROTRANSMITTERS
Endogenous opioid peptides are produced and often re-
leased together with other neurotransmitter molecules in
the brain, pituitary gland, and adrenal gland as well as by
single neurons in the central and peripheral nervous sys-
tems. For example, neurons in the carotid body simultane-
ously release an enkephalin and dopamine. Similarly,
single neurons in the peripheral nervous system of rats
simultaneously release an enkephalin and the neurotrans-
mitter norepinephrine.
Although the function of the co-release of peptide-
neurotransmitter pairs is not always clear, evidence sug-
gests that opioid peptides can alter the release of other
classic neurotransmitters. Opioid peptides generally make
their target neurons more difficult to excite by increasing
the voltage difference that exists between the inside and
the outside of the cell (i.e., by hyperpolarizing the neu-
rons). As a result of this hyperpolarization, the neuron’s
“firing rates” and neurotransmitter release are reduced.
However, if the neuron receiving the opioid peptide signal
is an inhibitory neuron (i.e., a neuron that reduces the ac-
tivity of the cells it affects), the opioid signal may inhibit
the inhibitory neuron, thereby producing excitation (i.e.,
disinhibition) of a neighboring cell.
Opioid peptides have been reported to inhibit the release
of acetylcholine, dopamine, and norepinephrine in both the
brain and the peripheral nervous system. In addition, opi-
oid peptides can increase as well as decrease the release of
serotonin and gamma-aminobutyric acid in the brain. The
integrated response to the administration of opioid peptides
in a given brain region is difficult to predict, because this
response depends on the excitatory versus inhibitory nature
of the cells or neurons that receive the opioid-peptide stim-
ulation. The fact that opioid peptides act as neuromodula-
tors, altering the release of other neurotransmitters, adds
another level of complexity to the neuronal networks in the
brain, spinal cord, and periphery that may contribute to
complex behaviors, such as alcohol consumption.
ALCOHOL AND THE ENDOGENOUS OPIOID SYSTEM
Evidence suggests that alcohol-induced activation of the
endogenous opioid system may be part of a neurobiologi-
cal mechanism that is involved in mediating alcohol re-
inforcement and excessive alcohol-drinking behavior. This
view is based on three lines of evidence.
The first line of evidence stems from analyses of the ef-
fects of opioid receptor antagonists on alcohol consumption.
Opioid receptor antagonists compete with the endogenous
opioid peptides for binding to the opioid peptide receptors, in
effect displacing the endogenous opioid peptides from the
receptors and thereby reversing the peptides’ effects. Thus,
when opioid receptor antagonists alter a biological process,
one can infer that endogenous opioid peptides are involved in
that process. Both nonselective opioid receptor antagonists
that affect all types of opioid receptors (e.g., naloxone and
naltrexone) and antagonists that are selective for the mu and
delta opioid receptor types have been shown to decrease
alcohol self-administration in rodents and monkeys under a
variety of experimental conditions.
Based on these findings, two double-blind, placebo-
controlled clinical trials investigated the effects of naltrex-
one on alcohol drinking in outpatient alcoholics. These
studies demonstrated that naltrexone decreased the mean
number of drinking days per week, the frequency of re-
lapse, the alcohol-induced subjective “high,” and the desire
to drink. In 1994 naltrexone (ReviaTM or Trexan®) was
approved by the Food and Drug Administration as a phar-
macotherapeutic agent for the treatment of alcohol depen-
dence when used as part of an appropriate plan of addiction
management. Naltrexone is the first pharmacotherapeutic
agent that decreases alcohol consumption by reducing the
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Figure 2 Schematic representation of a rat brain showing
the distribution of ß-endorphin–containing
neurons. Most of these neurons originate in the
arcuate nucleus in the hypothalamus. As indicated
by the arrows, the neurons extend to a variety of
brain regions, terminating in the shaded areas. 
NOTE: ac=n. amygdaloideus centralis; amg=amygdala;
ar=arcuate n.; CAI=capsula interna; pbl=n. parabranchialis
lateralis; pbm=n. parabranchialis medialis; pvr=n. periventricularis
rotundocellularis.
SOURCES: Finley, J.C.W.; Lindstrom, P.; and Petrusz, P.
Immunocytochemical localization of ß-endorphin-containing
neurons in the rat brain. Neuroendocrinology 33:28–42, 1981;
Konig, J.F.R., and Klippel, R.H. The Rat Brain. Baltimore: Williams
& Wilkins, 1963; Ungerstedt, U. Stereotaxic mapping of the
monoamine pathways in the rat brain. Acta Physiologica
Scandinavica 367(Suppl.):1–48, 1971.
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reinforcing properties of alcohol rather than by inducing
illness, as does disulfiram (Antabuse®).
The second line of evidence suggesting that endogenous
opioid peptides are involved in regulating alcohol-drinking
behavior comes from neurobiological studies indicating that
alcohol alters the activity within opioid peptide systems.
Acute alcohol consumption or the exposure of isolated cells
and tissues to alcohol increases endorphin and enkephalin
gene expression in certain brain regions of rodents, increas-
es opioid peptide release from both the brain and the
pituitary gland of rodents in tissue- and organ-culture
experiments, and increases opioid peptide release from the
pituitary of both rodents and humans in the intact organism.
Conversely, chronic alcohol administration decreases opi-
oid gene expression in rat brain, and chronic drinking de-
creases beta-endorphin release in alcoholics. 
The third line of evidence supporting the functional in-
volvement of the opioid system in alcohol-drinking behavior
is derived from studies indicating that both in rodents and in
humans, a genetic predisposition toward alcohol consump-
tion is accompanied by an increased responsiveness of the
opioid system to alcohol. For example, in a rat strain selec-
tively bred for high rates of alcohol consumption, acute
alcohol administration produces larger increases in beta-
endorphin gene expression in the pituitary and enkephalin
gene expression in the brain compared with rats selectively
bred for low alcohol consumption. Similarly, alcohol expo-
sure induces a greater and more prolonged release of opioid
peptides in brain tissue from alcohol-preferring mice com-
pared with tissue from mice that do not prefer alcohol.
In humans, beta-endorphin responses to alcohol differ
among subjects with and without a family history of alco-
holism. Thus, alcohol consumption induces a significant
increase in plasma beta-endorphin levels in subjects at high
risk for the future development of alcoholism (i.e., with a
family history of alcoholism), but not in those at low risk
(i.e., without a family history of alcoholism). Taken togeth-
er, these results from animal and human studies suggest
that genetic differences in alcohol-drinking behavior may
stem in part from variations in the responsiveness of the
opioid system to alcohol. 
ALCOHOL REINFORCEMENT AND THE ENDOGENOUS
OPIOID SYSTEM
Significant experimental evidence suggests that beta-
endorphin and the enkephalins function as positive rein-
forcers. In humans, a strong correlation exists between
feelings of well-being or euphoria and plasma levels of
beta-endorphin. In addition, beta-endorphin administration
into the fluid-filled cavities of the brain (i.e., the ventricles)
produces mood elevation. In rodents, both beta-endorphin
and the enkephalins act as reinforcers, as evidenced by the
fact that the animals self-administer opioid peptides and
prefer locations where they have received opioid peptides
in the past. Taken together, these observations suggest that
greater alcohol-induced activation of the endogenous opi-
oid system in genetically predisposed animals or humans
may enhance the reinforcing properties of alcohol, thereby
increasing the probability of subsequent drinking. This
effect may contribute to the development of a preference
for and the continued ingestion of alcohol. Enhanced re-
sponsiveness of the opioid system to alcohol may be a
heritable trait associated with, and causally related to,
excessive alcohol-drinking behavior.
SUMMARY
Research findings obtained over the past two decades have
suggested that opioid peptides serve a variety of physiologi-
cal functions. Moreover, alterations in endogenous opioid
peptide systems may contribute to a variety of clinical con-
ditions, including alcoholism, obesity, depression, diabetes,
and epilepsy. The release of opioid peptides in response to
alcohol consumption may reinforce further alcohol drink-
ing. Moreover, enhanced sensitivity of opioid peptide sys-
tems to alcohol may contribute to a predisposition for the
development of alcoholism in certain people. 
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THE ROLE OF THE
NEUROMODULATOR ADENOSINE
IN ALCOHOL’S ACTIONS
Douglas P. Dohrman, Ph.D.; Ivan Diamond,
M.D., Ph.D.; and Adrienne S. Gordon, Ph.D.
The interaction between the neuromodulator adenosine
and adenosine receptors on the surface of neurons mod-
ifies the neurons’ responses to neurotransmitters. The ac-
tivated adenosine receptors alter the levels of small
signaling molecules (i.e., second messengers) in the cells.
Depending on the receptors and cells involved, these
changes can make it easier or more difficult for neuro-
transmitters to excite the cell. Adenosine’s activity is reg-
ulated by proteins called nucleoside transporters, which
carry adenosine into and out of the cell. Alcohol inter-
feres with the function of the adenosine system. For ex-
ample, both acute and chronic alcohol exposure affect
the function of the adenosine-carrying nucleoside trans-
porters, thereby indirectly altering the second-messenger
levels in the cells. Through this mechanism, adenosine
may mediate some of alcohol’s effects, such as intoxica-
tion, motor incoordination, and sedation. KEY WORDS:
adenosine; neurotransmitters; receptors; neuron; cell sig-
naling; second messenger; nucleosides; biological trans-
port; brain; central nervous system; animal cell line;
human cell line; cAMP; signal transduction; AOD intox-
ication; motor coordination; sleep; literature review
Alcohol abuse and dependence are among the mostcommon and costly health problems worldwide. Inthe United States alone, nearly 7 percent of adults
are alcohol dependent. Furthermore, the consequences of
heavy drinking account for more than 20 percent of all
hospitalizations (Diamond and Gordon 1997). To address
the plethora of medical and social problems associated
with alcohol abuse and dependence and to identify the
mechanisms underlying the development of tolerance to
and dependence on alcohol, it is vital to understand alco-
hol’s interactions with various brain systems.
One chemical that modifies (i.e., modulates) brain func-
tion and has been implicated in several of alcohol’s acute
and chronic effects is adenosine. This article reviews cur-
rent knowledge about alcohol’s interactions with adenosine-
mediated modulation of nerve-cell activity in the central
nervous system (CNS). After summarizing adenosine’s role
in signal transmission in the CNS, this article discusses
studies investigating alcohol’s interactions with adenosine
in cell-culture (i.e., in vitro) models. Finally, the article
reviews the evidence that adenosine may be an important
mediator of alcohol’s effects in both animals and humans.
ADENOSINE IS A NEUROMODULATOR
Signal transmission among nerve cells, or neurons, is me-
diated primarily by neurotransmitter molecules that are
released from the signal-emitting (i.e., presynaptic) cell
and interact with specific molecules (i.e., receptors) on the
surface of the signal-receiving (i.e., postsynaptic) cell.1
This interaction results in the excitation or inhibition of the
postsynaptic cell. Adenosine also alters neuronal activity,
thereby affecting behavior; however, it does not meet all
the requirements for a neurotransmitter. For example,
adenosine by itself does not excite or inhibit postsynaptic
cells. Instead, adenosine regulates or modulates the activity
of neurons in response to other neurotransmitters; it is
therefore called a neuromodulator.
Adenosine is generated in all living cells during the
breakdown of adenosine triphosphate (ATP), which occurs
during most energy-requiring chemical reactions in the cell.
Large, channel-forming proteins2 called nucleoside trans-
porters then carry some of the adenosine out of the cells
into the fluid surrounding the cells (i.e., the extracellular
fluid). In addition, some neurons release ATP along with
their neurotransmitters. This ATP also is converted into
adenosine. The adenosine in the extracellular fluid can
interact with receptors on the surfaces of surrounding cells
(including the cell that released it) and modulate these cells’
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